EVLO
Closed
Evelo Biosciences Inc
0.0005
0.0000 (0.00%)
Last Update: 01 Jul 2025 16:30:00
Yesterday: 0.0005
Day's Range: 0.0005 - 0.0005
Send
sign up or login to leave a comment!
When Written:
0.1807
Evelo Biosciences Inc is a clinical-stage biotechnology company that is focused on developing monoclonal microbial therapeutics for the treatment of a range of diseases. The company's proprietary platform technology, known as the Microbiome Platform, is designed to harness the power of the human microbiome to develop therapies that target specific diseases.
Evelo Biosciences is headquartered in Cambridge, Massachusetts, and was founded in 2014 by Noubar Afeyan, Flagship Pioneering, and David Berry. The company went public in 2018 and is listed on the NASDAQ under the ticker symbol "EVLO."
The company's lead product candidate, EDP1815, is being developed for the treatment of psoriasis and other inflammatory diseases. Evelo Biosciences is also developing other product candidates targeting various diseases, including cancer, autoimmune disorders, and metabolic diseases.
Evelo Biosciences has partnerships with several leading pharmaceutical companies, including Merck, Sanofi, and Mayo Clinic. The company has received funding from several venture capital firms, including Flagship Pioneering, Polaris Partners, and GV.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Evelo Biosciences is headquartered in Cambridge, Massachusetts, and was founded in 2014 by Noubar Afeyan, Flagship Pioneering, and David Berry. The company went public in 2018 and is listed on the NASDAQ under the ticker symbol "EVLO."
The company's lead product candidate, EDP1815, is being developed for the treatment of psoriasis and other inflammatory diseases. Evelo Biosciences is also developing other product candidates targeting various diseases, including cancer, autoimmune disorders, and metabolic diseases.
Evelo Biosciences has partnerships with several leading pharmaceutical companies, including Merck, Sanofi, and Mayo Clinic. The company has received funding from several venture capital firms, including Flagship Pioneering, Polaris Partners, and GV.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!